AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11957164 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (15 mg/kg intravenously 1 hour before surgery and 0.3 mg/kg intravenously every 6 hours for 4 doses)
Number of subjects: 0
Study 11957164 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 0
Study 11957164 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (to lower cortisol during surgery)
Number of subjects: 0
Study 11957164 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (healthy volunteers)
Number of subjects: 0
Study 11957164 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone and placebo
Number of subjects: 0
Study 10410529 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for pancreatic endocrine tumors
Number of subjects: 18
Study 7586430 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate-verapamil (GV) solution
Number of subjects: 36
Study 7586430 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine (Pap)
Number of subjects: 36
Study 7586430 — intervention group
Group type: COMPARATOR
Intervention: Ringer's solution (untreated)
Number of subjects: 36
Study 2343724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 5 micrograms/kg injected after induction under thiopental anaesthesia
Number of subjects: 20
Study 2343724 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 5 micrograms/kg injected after induction under propofol anaesthesia
Number of subjects: 20
Study 7389482 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolin (new chemotherapeutic agent)
Number of subjects: 69
Study 7389482 — intervention group
Group type: COMPARATOR
Intervention: Conventional antibiotic therapy
Number of subjects: 69
Study 31122792 — intervention group
Group type: EXPERIMENTAL
Intervention: eReferral (electronic referral)
Number of subjects: 484
Study 31122792 — intervention group
Group type: COMPARATOR
Intervention: Control (manual referral)
Number of subjects: 484
Study 31122792 — intervention group
Group type: EXPERIMENTAL
Intervention: eReferral
Number of subjects: 484
Study 31122792 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 484
Study 28820950 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training for 24 weeks
Number of subjects: 556
Study 28820950 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control group
Number of subjects: 556
Study 26337448 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of red wine grape pomace flour (WGPF) per day
Number of subjects: 38
Study 26337448 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 13)
Number of subjects: 38
Study 23295262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intanza 15 μg intradermal vaccine
Number of subjects: 500
Study 23295262 — intervention group
Group type: COMPARATOR
Intervention: Inflexal V virosomal adjuvanted intramuscular vaccine
Number of subjects: 500
Study 22710530 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1.5mg/kg
Number of subjects: 72
Study 22710530 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200mg
Number of subjects: 72
Study 22710530 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200mg and Esmolol 1.5mg/kg
Number of subjects: 72
Study 22710530 — intervention group
Group type: COMPARATOR
Intervention: Placebo and Normal Saline
Number of subjects: 72
Study 22710530 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200mg and Normal Saline
Number of subjects: 72
Study 22710530 — intervention group
Group type: COMPARATOR
Intervention: Placebo and Esmolol 1.5mg/kg
Number of subjects: 72
Study 19366849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT) with glycemia target of 80-110 mg/dl
Number of subjects: 658
Study 19366849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 658
Study 19366849 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT) with glycemia target above 215 mg/dl
Number of subjects: 658
Study 16357619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol plus isosorbide mononitrate (medication group)
Number of subjects: 230
Study 16357619 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic treatment (sclerotherapy or ligation) (control group)
Number of subjects: 230
Study 15210660 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulphate
Number of subjects: 75
Study 15210660 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbitone
Number of subjects: 75
Study 11527789 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry-driven community-based outreach
Number of subjects: 1856
Study 11527789 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 1856
Study 9324621 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression resuscitation (ACD-CPR)
Number of subjects: 0
Study 9324621 — intervention group
Group type: COMPARATOR
Intervention: Standard manual CPR (S-CPR)
Number of subjects: 0
Study 8129382 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia combined with irradiation and chemotherapy (HCR)
Number of subjects: 0
Study 8129382 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and radiotherapy (CR)
Number of subjects: 0
Study 8129382 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 8129382 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia combined with irradiation and chemotherapy (HCR) with cisplatin
Number of subjects: 0
Study 8129382 — intervention group
Group type: COMPARATOR
Intervention: Multi-drug combined treatment from other institutes
Number of subjects: 0
Study 2656902 — intervention group
Group type: COMPARATOR
Intervention: Felodipine extended release (10 mg)
Number of subjects: 14
Study 2656902 — intervention group
Group type: COMPARATOR
Intervention: Felodipine plain tablet (10 mg)
Number of subjects: 14
Study 31437698 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 30
Study 31437698 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 30
Study 26595963 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with yellow turpentine bathtubs and bronchodilators inhalations (atrovent inhalations).
Number of subjects: 89
Study 26595963 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with yellow turpentine bathtubs alone.
Number of subjects: 89
Study 26595963 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic physical exercises and symptomatic medications (control group).
Number of subjects: 89
Study 23887469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (n=30)
Number of subjects: 47
Study 23887469 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Control group, n=17)
Number of subjects: 47
Study 21912335 — intervention group
Group type: COMPARATOR
Intervention: Sleep-inducing medication (specific agents not detailed), administered over a 2-week period.
Number of subjects: 40
Study 21912335 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) monitoring conducted for three consecutive nights each week, without medication on the first night as a baseline.
Number of subjects: 40
Study 21912335 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational assessments (awake, drowsy, or asleep) recorded every 15 minutes during PSG monitoring.
Number of subjects: 40
Study 19552057 — intervention group
Group type: EXPERIMENTAL
Intervention: 61-points relaxation training (61-PR) for 1 week
Number of subjects: 50
Study 19552057 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 19552057 — intervention group
Group type: COMPARATOR
Intervention: Cold pressor test (CPT)
Number of subjects: 50
Study 21977250 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/daily)
Number of subjects: 57
Study 21977250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/daily)
Number of subjects: 57
Study 21977250 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (losartan 50 mg/ramipril 5 mg/daily)
Number of subjects: 57
Study 12825849 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of breast cancer (v.s. no family history)
Number of subjects: 160
Study 12825849 — intervention group
Group type: EXPERIMENTAL
Intervention: High body mass index (> or = 30kg/m2 v.s. < 30kg/m2)
Number of subjects: 160
Study 12825849 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobular breast cancer histology (v.s. ductal)
Number of subjects: 160
Study 12825849 — intervention group
Group type: COMPARATOR
Intervention: Menopausal status, prior hormone replacement therapy, and estrogen/progesterone receptor status of the breast tumors
Number of subjects: 160
Study 11052901 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8673189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketamine (KET) 4 mg/kg with atropine sulfate 0.01 mg/kg
Number of subjects: 29
Study 8673189 — intervention group
Group type: COMPARATOR
Intervention: Combined meperidine, promethazine, and chlorpromazine (MPC)
Number of subjects: 29
Study 1883251 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene (2.5 mg oral dose)
Number of subjects: 0
Study 1883251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6416476 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide (250 mg)
Number of subjects: 637
Study 6416476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 637
Study 6416476 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term chlorpropamide
Number of subjects: 637
Study 6416476 — intervention group
Group type: COMPARATOR
Intervention: Non-insulin dependent diabetics (not on long term chlorpropamide)
Number of subjects: 637
Study 6416476 — intervention group
Group type: COMPARATOR
Intervention: Insulin dependent diabetics
Number of subjects: 637
Study 6416476 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetics
Number of subjects: 637
Study 30866834 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame training combined with daily fish oil supplementation (omega-3 fatty acids)
Number of subjects: 58
Study 30866834 — intervention group
Group type: COMPARATOR
Intervention: Exergame training
Number of subjects: 58
Study 30866834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 58
Study 30866834 — intervention group
Group type: COMPARATOR
Intervention: Olive oil supplementation
Number of subjects: 58
Study 27742914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lying flat head position for ≥24 hours
Number of subjects: 0
Study 27742914 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 27555374 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oral and maxillofacial treatment with 3-monthly dental follow-ups
Number of subjects: 253
Study 27555374 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring and treatment by the patient's dentist
Number of subjects: 253
Study 23582194 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy (LA)
Number of subjects: 868
Study 23582194 — intervention group
Group type: COMPARATOR
Intervention: Open appendicectomy (OA)
Number of subjects: 868
Study 21762224 — intervention group
Group type: EXPERIMENTAL
Intervention: OC000459 200 mg twice daily
Number of subjects: 132
Study 21762224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 20003483 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement Assessment Battery for Children (MABC)
Number of subjects: 20
Study 20003483 — intervention group
Group type: EXPERIMENTAL
Intervention: MABC subtest ABC‐Ball skills
Number of subjects: 20
Study 20003483 — intervention group
Group type: EXPERIMENTAL
Intervention: Clubfoot Assessment Protocol (CAP) item 'one‐leg stand'
Number of subjects: 20
Study 17508839 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser therapy with an energy dose of 0.275 J per tender point for nine sessions
Number of subjects: 39
Study 17508839 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation (placebo group) for nine sessions
Number of subjects: 39
Study 15374729 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of finasteride every day
Number of subjects: 38
Study 15374729 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg of finasteride every 3 days
Number of subjects: 38
Study 11435249 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice a day
Number of subjects: 45
Study 11435249 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 microg twice a day
Number of subjects: 45
Study 11435249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 11435249 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control)
Number of subjects: 45
Study 9862946 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected adults receiving medical care
Number of subjects: 4042
Study 8991823 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological and immunohistochemical findings in group A patients
Number of subjects: 20
Study 8991823 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological findings in group B patients
Number of subjects: 20
Study 8991823 — intervention group
Group type: COMPARATOR
Intervention: Histological findings in controls
Number of subjects: 20
Study 8991823 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical findings in group A patients
Number of subjects: 20
Study 8991823 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical findings in group B patients
Number of subjects: 20
Study 8991823 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunological pattern hypothesis
Number of subjects: 20
Study 2684175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (120 mg daily dose, 40 mg administered 3 times daily for 8 weeks)
Number of subjects: 36
Study 2684175 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 36
Study 238716 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (Tenormin)
Number of subjects: 11
Study 238716 — intervention group
Group type: COMPARATOR
Intervention: Practolol and placebo
Number of subjects: 11
Study 30943980 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOhigh + almonds
Number of subjects: 24
Study 30943980 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOhigh
Number of subjects: 24
Study 28606441 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D therapy (50,000 IU of vitamin D3 intramuscularly monthly for six months)
Number of subjects: 85
Study 28606441 — intervention group
Group type: COMPARATOR
Intervention: Control group (distilled water, 0.25mL monthly for six months)
Number of subjects: 85
Study 25512407 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole i.v. solution (doses: 0, 50, 100, 200, 250, 300 mg)
Number of subjects: 72
Study 25512407 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole i.v. solution (100 mg)
Number of subjects: 72
Study 25512407 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (0 mg)
Number of subjects: 72
Study 25512407 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 72
Study 25512407 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 72
Study 25512407 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of i.v. posaconazole
Number of subjects: 72
Study 24498962 — intervention group
Group type: EXPERIMENTAL
Intervention: R&R2MHP cognitive skills program
Number of subjects: 59
Study 24498962 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 59
Study 21449783 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus peginterferon-ribavirin for 44 weeks (Control Group 1)
Number of subjects: 1097
Study 21449783 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir plus peginterferon-ribavirin for 24 weeks (Group 2)
Number of subjects: 1097
Study 21449783 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir plus peginterferon-ribavirin for 44 weeks (Group 3)
Number of subjects: 1097
Study 19894383 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Zhebei Granules (CZG)
Number of subjects: 137
Study 19894383 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 137
Study 16380311 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychic healing treatment (exact dosage and duration not specified)
Number of subjects: 20
Study 16380311 — intervention group
Group type: COMPARATOR
Intervention: Control condition (exact details not specified)
Number of subjects: 20
Study 16380311 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment and control groups (belief in psychic healing)
Number of subjects: 20
Study 15697056 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious Depression (MDD with high anxiety symptoms)
Number of subjects: 1450
Study 10967896 — intervention group
Group type: EXPERIMENTAL
Intervention: 2nd generation cephalosporin administered on the day of operation and every 8 hours for the next 24 hours; metronidazol for patients operated on trachea and oesophagus.
Number of subjects: 465
Study 10967896 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic treatment (before the introduction of the prophylactic regime).
Number of subjects: 465
Study 9075803 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg pramlintide
Number of subjects: 0
Study 9075803 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg pramlintide
Number of subjects: 0
Study 9075803 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg pramlintide
Number of subjects: 0
Study 9075803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8417429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (8 mg/kg/day, single dose)
Number of subjects: 63
Study 8417429 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (40 mg/kg/day, 3 divided doses)
Number of subjects: 63
Study 8417429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 63
Study 8417429 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 63
Study 3698066 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg TID
Number of subjects: 60
Study 3698066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31712803 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid and 30 mg elemental zinc daily for 6 months
Number of subjects: 2370
Study 31712803 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 6 months
Number of subjects: 2370
Study 30351342 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Star Rating (FoPL)
Number of subjects: 2069
Study 30351342 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Intake Guide (FoPL)
Number of subjects: 2069
Study 30351342 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Traffic Lights (FoPL)
Number of subjects: 2069
Study 30351342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient claim
Number of subjects: 2069
Study 30351342 — intervention group
Group type: EXPERIMENTAL
Intervention: General-level health claim
Number of subjects: 2069
Study 30351342 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-level health claim
Number of subjects: 2069
Study 27538776 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose intraoperative electron radiotherapy (IOERT)
Number of subjects: 71
Study 27538776 — intervention group
Group type: COMPARATOR
Intervention: Whole breast irradiation (WBI)
Number of subjects: 71
Study 24696094 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin 10 mg/d
Number of subjects: 323
Study 24696094 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin 30 mg/d
Number of subjects: 323
Study 24696094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 22324890 — intervention group
Group type: COMPARATOR
Intervention: GlideScope videolaryngoscope
Number of subjects: 60
Study 22324890 — intervention group
Group type: EXPERIMENTAL
Intervention: Shikani optical stylet
Number of subjects: 60
Study 20357295 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg)
Number of subjects: 0
Study 20357295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20357295 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (300-450 mg/d)
Number of subjects: 0
Study 18612570 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorical BAC information from the saliva test
Number of subjects: 959
Study 18612570 — intervention group
Group type: EXPERIMENTAL
Intervention: Precise (three-digit) BAC information from the breath alcohol analyzer
Number of subjects: 959
Study 18612570 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorical BAC information corroborated by a calibrated police breath alcohol analyzer
Number of subjects: 959
Study 18612570 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no BAC feedback provided)
Number of subjects: 959
Study 18612570 — intervention group
Group type: EXPERIMENTAL
Intervention: All BAC information conditions
Number of subjects: 959
Study 15891317 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 89
Study 15891317 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 89
Study 15891317 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) and Propofol
Number of subjects: 89
Study 12017347 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral eletriptan (1.5-30 mg or 30-120 mg)
Number of subjects: 55
Study 12017347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous eletriptan (1.67-50 microg/kg or 50-102 microg/kg)
Number of subjects: 55
Study 12017347 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral eletriptan
Number of subjects: 55
Study 12017347 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral eletriptan doses > or = 60 mg
Number of subjects: 55
Study 12017347 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan
Number of subjects: 55
Study 9915433 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy
Number of subjects: 365